Decline Expected in HIV Care Providers in Next Five Years
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
FRIDAY, Nov. 8, 2024 -- The supply of health care professionals available to provide HIV care is expected to continue to decline over the next five years, according to research published in the November/December issue of the Journal of the Association of Nurses in AIDS Care.
Andrea Norberg, D.N.P., R.N., from the Rutgers School of Nursing in Newark, New Jersey, and colleagues conducted an anonymous survey of 1,004 prescribing clinicians currently providing HIV-related health care.
The researchers found that clinicians who were younger and Black, advanced practice registered nurses, and family medicine physicians were more likely to report continuing with the same number of patients or increasing the number of patients in their HIV practice in the next five years. However, 17.8 percent of respondents reported plans to stop HIV clinical care wholly or to decrease the number of people living with HIV in their practice over the next five years. Retirement, administrative burden, and burnout were the most common reasons for leaving.
"Our study provides new insights into the numbers and characteristics of clinicians who will be available to provide HIV care in the coming years," Norberg said in a statement. "This information will inform efforts to build the HIV workforce amid the ongoing shift from specialist care to primary care strategies."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-11-10 00:00
Read more
- SABCS: Imlunestrant Tied to Improved PFS for ER-Positive, HER2-Negative Breast Cancer With ESR1 Mutations
- Scientists Develop Whole New Form of Effective Asthma Treatment
- Check Your Pantry, Lay's Classic Potato Chips Recalled Due to Milk Allergy Risk
- FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis
- Zepbound Slashes Diabetes Risk in Obese Users
- Risk for Head and Neck Cancer Lower for Coffee and Tea Drinkers
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions